170 related articles for article (PubMed ID: 36214894)
1. Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivo.
Yang R; Dong S; Zhang J; Zhu S; Miao G; Zhang B
Mol Cell Biochem; 2023 May; 478(5):1031-1044. PubMed ID: 36214894
[TBL] [Abstract][Full Text] [Related]
2. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
3. Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
Ge S; Zhang Q; Chen Y; Tian Y; Yang R; Chen X; Li F; Zhang B
Toxicol Appl Pharmacol; 2021 Mar; 415():115450. PubMed ID: 33577917
[TBL] [Abstract][Full Text] [Related]
4. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
Tian Y; Yang W; Yang R; Zhang Q; Hao L; Bian E; Yang Y; Huang X; Wu Y; Zhang B
Toxicol Appl Pharmacol; 2022 Jan; 435():115829. PubMed ID: 34919946
[TBL] [Abstract][Full Text] [Related]
6. PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Bajbouj K; Ramakrishnan RK; Saber-Ayad M; Omar HA; Saheb Sharif-Askari N; Shafarin J; Elmoselhi AB; Ihmaid A; AlHaj Ali S; Alalool A; Abdullah R; Hamid Q
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200178
[TBL] [Abstract][Full Text] [Related]
7. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
[TBL] [Abstract][Full Text] [Related]
8. Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer
Dong SH; Wang X; Tian SC; Ma NQ; Zhang XY; Liu Y; Zhang BL; Wu YJ
Pharmazie; 2018 May; 73(5):269-273. PubMed ID: 29724292
[TBL] [Abstract][Full Text] [Related]
9. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
10. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Jing P; Zhao N; Ye M; Zhang Y; Zhang Z; Sun J; Wang Z; Zhang J; Gu Z
Cancer Lett; 2018 Jul; 427():38-48. PubMed ID: 29679612
[TBL] [Abstract][Full Text] [Related]
11. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
12. EGPI-1, a novel eIF4E/eIF4G interaction inhibitor, inhibits lung cancer cell growth and angiogenesis through Ras/MNK/ERK/eIF4E signaling pathway.
Qi X; Zhang S; Chen Z; Wang L; Zhu W; Yin C; Fan J; Wu X; Wang J; Guo C
Chem Biol Interact; 2022 Jan; 352():109773. PubMed ID: 34902296
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.
Gu Z; Gao S; Zhang F; Wang Z; Ma W; Davis RE; Wang Z
Biochem J; 2012 Sep; 446(2):235-41. PubMed ID: 22708516
[TBL] [Abstract][Full Text] [Related]
14. PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer.
Hu R; Zhou B; Chen Z; Chen S; Chen N; Shen L; Xiao H; Zheng Y
Front Immunol; 2021; 12():722188. PubMed ID: 35111150
[TBL] [Abstract][Full Text] [Related]
15. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
Scoumanne A; Zhang J; Chen X
Nucleic Acids Res; 2009 Aug; 37(15):4965-76. PubMed ID: 19528079
[TBL] [Abstract][Full Text] [Related]
16. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
[No Abstract] [Full Text] [Related]
17. Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/β-catenin.
Cai S; Wang P; Xie T; Li Z; Li J; Lan R; Ding Y; Lu J; Ye J; Wang J; Li Z; Liu P
Pharmacol Res; 2020 Nov; 161():105104. PubMed ID: 32739429
[TBL] [Abstract][Full Text] [Related]
18. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
Jiang H; Zhu Y; Zhou Z; Xu J; Jin S; Xu K; Zhang H; Sun Q; Wang J; Xu J
Cancer Med; 2018 Mar; 7(3):869-882. PubMed ID: 29441724
[TBL] [Abstract][Full Text] [Related]
19. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Saha K; Fisher ML; Adhikary G; Grun D; Eckert RL
Carcinogenesis; 2017 Aug; 38(8):827-836. PubMed ID: 28854561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
